Gemtuzumab ozogamicin |
| Catalog No.GC64479 |
Gemtuzumab ozogamicin est un conjugué anticorps-médicament (ADC) composé d'un anticorps monoclonal ciblant CD33 lié à un dérivé cytotoxique de Calichéamicine. Gemtuzumab ozogamicin peut être utilisé pour la recherche sur la leucémie myéloïde aiguë.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 220578-59-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) consisting of a monoclonal antibody targeting CD33 linked to a cytotoxic derivative of Calicheamicin. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia[1].
[1]. Baron J, et al. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia. Expert Rev Clin Pharmacol. 2018;11(6):549-559.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *